Formulation-Based Cost Savings With Cabozantinib Capsules

This Viewpoint asserts that the formulation (tablet vs capsule) and the dosage of cabozantinib can be optimized to reduce toxicities and cost while maintaining efficacy.

Authors

Institutions

Publication Details

Journal
JAMA Oncology
Published
2025-04-03
DOI
https://doi.org/10.1001/jamaoncol.2025.0175
Citations
1
Primary Topic
Lung Cancer Treatments and Mutations
Type
article
Field-Weighted Citation Impact
1.52
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Formulation-Based Cost Savings With Cabozantinib Capsules

Austin Wesevich, Walter M. Stadler, Mark J. Ratain
1 citations
JAMA Oncology
Lung Cancer Treatments and Mutations
1.52
article

Formulation-Based Cost Savings With Cabozantinib Capsules

Austin Wesevich, Walter M. Stadler, Mark J. Ratain
article en
1 citations

Abstract

This Viewpoint asserts that the formulation (tablet vs capsule) and the dosage of cabozantinib can be optimized to reduce toxicities and cost while maintaining efficacy.

JAMA OncologyVol. 11(6)
University of Chicago (US)
Zero hunger
Openalex Percentile: Top 20%
Lung Cancer Treatments and Mutations
1.52
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Formulation-Based Cost Savings With Cabozantinib Capsules — Austin Wesevich, Walter M. Stadler, et al. · JAMA Oncology (2025) | TGRS Research Map | TGRS